Výsledky vyhledávání - "Shaila Ballal"

Akademický článek

Behavioral changes in patients with Prader-Willi syndrome receiving diazoxide choline extended-release tablets compared to the PATH for PWS natural history study

Autor: Theresa V. Strong, Jennifer L. Miller, Shawn E. McCandless, Evelien Gevers, Jack A. Yanovski, Lisa Matesevac, Jessica Bohonowych, Shaila Ballal, Kristen Yen, Patricia Hirano, Neil M. Cowen, Anish Bhatnagar

Publikováno v: Journal of Neurodevelopmental Disorders, Vol 16, Iss 1, Pp 1-9 (2024)

Abstract Background Prader-Willi syndrome (PWS) is a rare neurobehavioral-metabolic disease caused by the lack of paternally expressed genes in the chromosome 15q11-q13 region, characterized by hypotonia, neurocognitive problems, behavioral difficult

Externí odkaz: https://doaj.org/article/f5daf70833c04bcc97d36ae2f517d1a7

Zobrazit plný text záznamu

Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study

Autor: Gary T. Ferguson, Kimberly Rossman, Dave Singh, Roopa Trivedi, Earl St Rose, Shaila Ballal, Paul Dorinsky, Fernando J. Martinez, Magnus Aurivillius, Patrick Darken, Colin Reisner, Klaus F. Rabe, Jadwiga A. Wedzicha, Chen Wang

Publikováno v: American Journal of Respiratory and Critical Care Medicine

Rationale: In the phase III, 52-week ETHOS (Efficacy and Safety of Triple Therapy in Obstructive Lung Disease) trial in chronic obstructive pulmonary disease (COPD) (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a1058cbdb73d18dbf60fe345e32e86a
http://europepmc.org/articles/PMC7924571

Zobrazit plný text záznamu

Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis

Autor: Gary T. Ferguson, Ulf Holmgren, M.K. Siddiqui, Barinder Singh, Enrico De Nigris, Sumeet Attri, Shaila Ballal, Patrick Darken

Publikováno v: Advances in Therapy. 37:2956-2975

Triple inhaled corticosteroid/long-acting muscarinic antagonist/long-acting β2-agonist (ICS/LAMA/LABA) combination therapy is recommended for patients with chronic obstructive pulmonary disease (COPD) who experience further exacerbations/symptoms on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a92ceecafb8f25db994edf6c2d51f62c
https://doi.org/10.1007/s12325-020-01311-3

Zobrazit plný text záznamu

Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS

Autor: Rongchang Chen, Kiernan DeAngelis, Eric Bourne, Huijie He, Pryseley Nkouibert Assam, Ting Yang, Shaila Ballal, Rong Su, Chen Wang, Li Zhao, Paul Dorinsky, Jian Kang

Publikováno v: Advances in Therapy

Introduction This pre-specified subgroup analysis evaluated the efficacy and safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) triple therapy versus corresponding dual therapies in the China subgroup of the phase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8aebb2882b898769f76ec86202c393a3
https://doi.org/10.1007/s12325-020-01266-5

Zobrazit plný text záznamu

Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD

Autor: Eric Bourne, Gary T. Ferguson, Yoshikazu Inoue, Kiernan DeAngelis, Hiroshi Okada, Nobuya Hayashi, Masakazu Ichinose, Osamu Hataji, Klaus F. Rabe, Shaila Ballal, Paul Dorinsky, Magnus Aurivillius, Yasushi Fukushima, Colin Reisner, Mami Takikawa

Publikováno v: International Journal of Chronic Obstructive Pulmonary Disease

Masakazu Ichinose,1 Yasushi Fukushima,2 Yoshikazu Inoue,3 Osamu Hataji,4 Gary T Ferguson,5 Klaus F Rabe,6 Nobuya Hayashi,7 Hiroshi Okada,7 Mami Takikawa,7 Eric Bourne,8 Shaila Ballal,9 Kiernan DeAngelis,10 Magnus Aurivillius,11 Colin Reisner,9 Paul D

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cebea17bf9328c5d1ee322ed65c26717
http://europepmc.org/articles/PMC6934178

Zobrazit plný text záznamu

Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS

Autor: Fernando J. Martinez, Gary T. Ferguson, Eric Bourne, Magnus Aurivillius, Patrick Darken, Shaila Ballal, Colin Reisner, Paul Dorinsky

Publikováno v: International Journal of Chronic Obstructive Pulmonary Disease

Fernando J Martinez,1 Gary T Ferguson,2 Eric Bourne,3 Shaila Ballal,4 Patrick Darken,5 Magnus Aurivillius,6 Paul Dorinsky,3 Colin Reisner4 1Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, USA; 2Pulmonary Resear

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::569b6e76e00830cd059a7c3bda1b2c8c
https://pubmed.ncbi.nlm.nih.gov/33542624

Zobrazit plný text záznamu

Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis

Autor: Gary T. Ferguson, J. McLaren, Paul Dorinsky, Colin Reisner, Chen Wang, Dave Singh, Klaus F. Rabe, Earl St Rose, Fernando J. Martinez, Jadwiga A. Wedzicha, Magnus Aurivillius, Shaila Ballal, Roopa Trivedi, Patrick Darken

Publikováno v: Airway pharmacology and treatment.

Background: For patients who experience COPD exacerbations on LAMA/LABA, GOLD recommends step-up to ICS/LAMA/LABA triple therapy for those with blood eosinophil counts (EOS) ≥100 cells/mm3. In the 52-week ETHOS trial (NCT02465567), triple therapy w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::650ca57f65d3a168339f7c5026ade8c5
https://doi.org/10.1183/13993003.congress-2020.984

Zobrazit plný text záznamu

COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels

Autor: Paul Dorinsky, Roopa Trivedi, Patrick Darken, Jadwiga A. Wedzicha, Earl St Rose, Colin Reisner, Chen Wang, Magnus Aurivillius, Shaila Ballal, Dave Singh, Klaus F. Rabe, Gary T. Ferguson, J. McLaren, Fernando J. Martinez

Publikováno v: Airway pharmacology and treatment.

Background: In the 52-week ETHOS trial (NCT02465567), the triple fixed-dose combination BGF MDI containing 320 µg or 160 µg budesonide reduced the rate of moderate/severe COPD exacerbations vs dual therapies. Objective: To assess exacerbation rates

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f9d0d65c45bebb1c60808b633c7b865d
https://doi.org/10.1183/13993003.congress-2020.977

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání